Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Athira Pharma stock | $11.76

Learn how to easily invest in Athira Pharma stock.

Athira Pharma Inc is a biotechnology business based in the US. Athira Pharma shares (ATHA) are listed on the NASDAQ and all prices are listed in US Dollars. Athira Pharma employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Athira Pharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATHA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Athira Pharma stock price (NASDAQ: ATHA)

Use our graph to track the performance of ATHA stocks over time.

Athira Pharma shares at a glance

Information last updated 2021-10-23.
Latest market close$11.76
52-week range$8.88 - $34.79
50-day moving average $9.88
200-day moving average $13.24
Wall St. target price$39.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.45

Buy Athira Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Athira Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athira Pharma price performance over time

Historical closes compared with the close of $11.76 from 2021-10-26

1 week (2021-10-20) 22.37%
1 month (2021-09-27) 19.63%
3 months (2021-07-27) 20.00%
6 months (2021-04-27) -36.36%
1 year (2020-10-27) -37.31%
2 years (2019-10-23) N/A
3 years (2018-10-23) N/A
5 years (2016-10-23) N/A

Athira Pharma financials

Gross profit TTM $0
Return on assets TTM -12.27%
Return on equity TTM -18.09%
Profit margin 0%
Book value $9.42
Market capitalisation $399.4 million

TTM: trailing 12 months

Shorting Athira Pharma shares

There are currently 1.1 million Athira Pharma shares held short by investors – that's known as Athira Pharma's "short interest". This figure is 16% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Athira Pharma shares can be evaluated.

Athira Pharma's "short interest ratio" (SIR)

Athira Pharma's "short interest ratio" (SIR) is the quantity of Athira Pharma shares currently shorted divided by the average quantity of Athira Pharma shares traded daily (recently around 310373.22404372). Athira Pharma's SIR currently stands at 3.66. In other words for every 100,000 Athira Pharma shares traded daily on the market, roughly 3660 shares are currently held short.

To gain some more context, you can compare Athira Pharma's short interest ratio against those of similar companies.

However Athira Pharma's short interest can also be evaluated against the total number of Athira Pharma shares, or, against the total number of tradable Athira Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athira Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Athira Pharma shares in existence, roughly 30 shares are currently held short) or 0.0354% of the tradable shares (for every 100,000 tradable Athira Pharma shares, roughly 35 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Athira Pharma.

Find out more about how you can short Athira Pharma stock.

Athira Pharma share dividends

We're not expecting Athira Pharma to pay a dividend over the next 12 months.

Athira Pharma overview

Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc.

Frequently asked questions

What percentage of Athira Pharma is owned by insiders or institutions?
Currently 4.772% of Athira Pharma shares are held by insiders and 67.644% by institutions.
How many people work for Athira Pharma?
Latest data suggests 20 work at Athira Pharma.
When does the fiscal year end for Athira Pharma?
Athira Pharma's fiscal year ends in December.
Where is Athira Pharma based?
Athira Pharma's address is: 18706 North Creek Parkway, Bothell, WA, United States, 98011-2141
What is Athira Pharma's ISIN number?
Athira Pharma's international securities identification number is: US04746L1044

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site